wire - news in brief

« BACK

Business/Economics



Results 1 - 50 of 333.
1 2 3 4 5 7 Next »

Business/Economics - Environment/Sustainable Development
22.02.2017
Reduction of energy consumption and CO2 emissions: promotion or steering?
Policy interventions to reduce energy consumption and CO2 emissions have a variety of effects on the economy and on households.
Business/Economics
13.02.2017
Financial windfall for young scientists
Financial windfall for young scientists
On February 2nd the EU approved Empa's «COFUND» application for financial support to the tune of more than ‘3.5 million, thereby securing partial funding for 50 post-doc positions at Empa over the next five years within the framework of the EU's Marie Sk'odowska-Curie actions.
Environment/Sustainable Development - Business/Economics
01.02.2017
User feedback is essential, especially for complex technology
User feedback is essential, especially for complex technology
Environmentally friendly, low-carbon energy technologies are needed to achieve global climate targets.
Business/Economics - Life Sciences
31.01.2017
In cold water
In cold water
Martin Ostermaier wanted to break out of the comfort zone of science. Now, instead of pipettes, the biochemist is dealing with investors and patent law.
Business/Economics - Administration/Government
31.01.2017
Opening doors in Asia
Opening doors in Asia
Both science and Swiss businesses are benefiting from the ETH science hub in Singapore. The newly founded Switzerland Technology Impact Platform (STIP) is helping Swiss SMEs to gain a foothold in Asia.
Business/Economics
30.01.2017
Towards better forecasts of slab avalanches
Towards better forecasts of slab avalanches
A team of researchers from EPFL and the SLF has developed a new model that describes how slab avalanches release.
Life Sciences - Business/Economics
30.01.2017
The Attraction Effect: how our Brains Can Be Influenced
The Attraction Effect: how our Brains Can Be Influenced
The decisions we make are influenced by other possibilities that we did not choose. At the same time, the options we missed out on determine our satisfaction with the outcomes of situations we were unable to control. Psychologists from the University of Basel conducted two experiments: first, they studied the decision-making behavior of students and, second, they measured brain activity and satisfaction when a set of possibilities is supplemented with another alternative.
Physics/Materials Science - Business/Economics
26.01.2017
‘Additive Manufacturing' speeds up
‘Additive Manufacturing’ speeds up
Empa offers Switzerland a platform to exchange information and knowhow in the field of Additive Manufacturing: During a technology briefing held at Empa Academy on January 18, experts from industry a
Medicine/Pharmacology - Business/Economics
26.01.2017
Inability to Work: Medical Experts Often Disagree
Independent medical evaluations are often used to adjudicate disability claims. But different doctors assessing the same patient often disagree on whether the patient is disabled or not. This problem can be mitigated by applying standardized procedures, says an international study led by researchers at the University of Basel and the University Hospital Basel in Switzerland.
Business/Economics - Medicine/Pharmacology
25.01.2017
Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback
Novartis delivered solid 2016 performance, with Growth Products absorbing Gleevec US LOE; innovation momentum continued; announces share buyback FY net sales (0% cc ) in line with prior year due to st
Medicine/Pharmacology - Business/Economics
20.12.2016
Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc
Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc.
Business/Economics
16.12.2016
Switzerland ratifies Croatia protocol
Bern, 16.12.2016 - Switzerland has ratified the protocol extending the free movement of persons to Croatia.
Medicine/Pharmacology - Business/Economics
16.12.2016
Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited
Acquisition to add a once-daily oral H 4 receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline    Investigational ZPL389 showed a clinically and statistically significant improvement of eczema lesions, leading to a 50% reduction in EASI score compared to placebo after eight weeks of treatment with a favorable safety profile   Eczema is a chronic, inflammatory skin condition a
Business/Economics - Careers/Employment
09.12.2016
Business/Economics - Astronomy
01.12.2016
President Schneider-Ammann attends ESA Ministerial Council
Bern, 01.12.2016 - On 1 December, President Johann N. Schneider-Ammann addressed the ministers of the 22 member states of the European Space Agency ESA and Canada in Lucerne.
Business/Economics - Computer Science/Telecom
01.12.2016
Swiss businesses are good process innovators
Swiss businesses are good process innovators
Switzerland's economy is facing some tough challenges: technologies are developing rapidly, processes are being amalgamated both inside and outside production facilities, and business units are becoming increasingly interconnected.
Medicine/Pharmacology - Business/Economics
29.11.2016
Novartis Access shares one-year learnings and announces memorandum of understanding with Rwanda
Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than 100
Medicine/Pharmacology - Business/Economics
21.11.2016
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options   Results of SUSTAIN will be presented
Business/Economics
18.11.2016
Transitioning the publication system towards Open Access: Study proposes pragmatic scenario
Transitioning the publication system towards Open Access: Study proposes pragmatic scenario
For the first time, a study has developed scenarios for restructuring transitioning Switzerland's scientific publication system towards Open Access (OA). The study was initiated by the SNSF in collaboration with the Scientific Information programme (SUC P-2) run by swissuniversities. It recommends a model that proposes a pragmatic and flexible way of making publicly funded research freely available at no charge and with no delay.
Business/Economics
04.11.2016
Switzerland intensifies relations with Mexico
Bern, 04.11.2016 - President Johann N. Schneider-Ammann has paid a two-day presidential visit to Mexico.
Careers/Employment - Business/Economics
26.10.2016
A 10 million euro round of financing for the start up Coorpacademy
A 10 million euro round of financing for the start up Coorpacademy
Coorpacademy, a startup based in EPFL's Innovation Park, has completed a 10 million euro round of financing.
Business/Economics - Medicine/Pharmacology
25.10.2016
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters Q3 net sales (-1% cc and USD) broadly in line wit
Business/Economics
21.10.2016
Business/Economics - Architecture
06.10.2016
Business/Economics - Politics
30.09.2016
Seven new professorships at the Department of Economics
The University of Zurich has proven that it can meet several US elite universities at eye level when it comes to recruiting the best talents.
Medicine/Pharmacology - Business/Economics
28.09.2016
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need   Sandoz "HACk" - Healthcare Access Challenge - is a compe
Business/Economics - Administration/Government
23.09.2016
Medicine/Pharmacology - Business/Economics
22.09.2016
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites   KAF156, currently in phase IIb, is the first compound from a novel class of antimalarials known as imidazolopiperazines   Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies; Novartis
Medicine/Pharmacology - Business/Economics
19.09.2016
Medicine/Pharmacology - Business/Economics
15.09.2016
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine days compared to placebo   Chronic migraine is the most disabling form of the disease, and is associated with substantial personal pain and disability, and financial cost to society ,   AMG 334 is being co-developed by Novartis and Amgen for the preventi
Business/Economics - Administration/Government
14.09.2016
New funding programme to serve as launch pad for Swiss start-ups
Bern, 14.09.2016 - This autumn, the European Space Agency (ESA) and the State Secretariat for Education, Research and Education (SERI) will open an ESA Business Incubation Centre (ESA BIC) in Switzerland.
Business/Economics
07.09.2016
Industry meets science
Industry meets science
A record number of visitors attended this year's Industry Day. Around 550 representatives from industry and business met with scientists for a lively debate on the Hönggerberg.
Agronomy/Food Science - Business/Economics
01.09.2016
Nadja El Benni to head ‘Competitiveness and System Evaluation' Research Division
Nadja El Benni to head ‘Competitiveness and System Evaluation’ Research Division
Bern, 01.09.2016 - Dr. Nadja El Benni was appointed Head of the ‘Competitiveness and System Evaluation' Strategic Research Division by Agroscope Council on 25 August 2016.
Business/Economics - Mechanical Engineering/Mechanics
18.08.2016
Super stair-climbers
Super stair-climbers
They have big ambitions: nine students from ETH Zurich and ZHdK are preparing to take on developers from renowned manufacturers and universities from around the world with their "Scewo" wheelchair at the Cybathlon.
Computer Science/Telecom - Business/Economics
16.08.2016
Innovative IT solution to tackle cyber crime
Innovative IT solution to tackle cyber crime
An ETH spin-off, xorlab, has ambitious plans: it has developed a unique IT security solution that provides more effective protection against hacker attacks.
Administration/Government - Business/Economics
28.07.2016
More than two million dollars to rethink cybersecurity
!- 28.07.16 - Cyberhaven is developing a new concept for information security. The EPFL spin-off is opening its second office in Boston and has raised more than 2 million dollars in venture capital.
Business/Economics - Medicine/Pharmacology
19.07.2016
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects Q2 net sales were flat (0% cc ) as Growth Produc
Medicine/Pharmacology - Business/Economics
13.07.2016
Sandoz biosimilar etanercept recommended by FDA advisory committee for approval to treat multiple inflammatory diseases
Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product                                                                
Business/Economics - Medicine/Pharmacology
23.06.2016
Medicine/Pharmacology - Business/Economics
15.06.2016
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundati
Medicine/Pharmacology - Business/Economics
08.06.2016
Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx at two years had no radiographic progression in the spine or joints , respectively ,     Cosentyx may
Medicine/Pharmacology - Business/Economics
25.05.2016
Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
Outlines actions underway to accelerate launch of Entresto , including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx Highlights leading pipeline of second
Medicine/Pharmacology - Business/Economics
24.05.2016
Sandoz’ biosimilar rituximab regulatory submission accepted by European Medicines Agency
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in the reference product's label Sandoz'
Medicine/Pharmacology - Business/Economics
21.05.2016
Novartis’ Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals
Novartis' Entresto given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals US guidelines now recommend Entresto as standard of care
Medicine/Pharmacology - Business/Economics
20.05.2016
Business/Economics
20.05.2016
NEST: building of the future is up and
A unique research and innovation platform has opened its doors: on 23 May 2016, the modular experimental building NEST was inaugurated on the Dübendorf campus of the two research institutes Empa and Eawag.
Medicine/Pharmacology - Business/Economics
19.05.2016
Novartis announces investment in FortiHFy clinical program of Entresto and heart failure
Forti fying H eart F ailure clinical evidence and patient qualit y of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials   The global clinical program will generate additional data on symptom reduction, efficacy, safety, quality of life benefits and real world evidence with Entresto   Investigators and patients from over 50 countries to participate over 5 years - Novartis today announced the establishment
1 2 3 4 5 7 Next »